Back to search

Peptide record

TPDB10485

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Neurotoxin Toxicity standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10485
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Neurotoxin Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP pep-lab Peptipedia AFP-GFuse Antifungipept CAFPdb AI4AVP dbAMP 3.0 DRAVP 2.0 CellPPD-MOD CPPsite3.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis NTxPred2 ToxinPred 3.0
standard
No
A 25-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
IWLTALKFLGKHAAKHLAKQQLSKL
Physicochemical Analysis
C135H223N37O30
RNDCEMPYV
L
2844.49
11.12
7
0
13
+5
0.98
0.064
125.20
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
5500
193.36
4
Residue Composition
number
4
A
0
R
0
N
0
D
0
C
0
E
2
Q
1
G
2
H
1
I
6
L
5
K
0
M
1
F
0
P
1
S
1
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 4 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 2 G: 1 H: 2 I: 1 L: 6 K: 5 M: 0 F: 1 P: 0 S: 1 T: 1 W: 1 Y: 0 V: 0
Chemical Descriptors
25
C135H223N37O30
2844.49
11.12
+5
0.98
0.064
Evidence Records 25 records
Evidence 1 Activity

Activity

MIC
Antibacterial
10-20 µM

Target

Escherichia coli D31

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram-negative bacteria E. coli D31 (MIC 10-20 uM) and weakly active against yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this
Evidence 2 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP DRAMP

Other

yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menouse
Evidence 3 Activity

Activity

MIC
Antibacterial
25 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

cans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J
Evidence 4 Activity

Activity

MIC
Antibacterial
6.25 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

(this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402).
Evidence 5 Activity

Activity

MIC
Antibacterial
6.25 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

t S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). This peptide also inhibits Escher
Evidence 6 Activity

Activity

MIC
Antifungal
10-20 µM

Target

Escherichia coli D31

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram-negative bacteria E. coli D31 (MIC 10-20 uM) and weakly active against yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this
Evidence 7 Activity

Activity

MIC
Antifungal
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menouse
Evidence 8 Activity

Activity

MIC
Antifungal
25 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

cans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J
Evidence 9 Activity

Activity

MIC
Antifungal
6.25 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402).
Evidence 10 Activity

Activity

MIC
Antifungal
6.25 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

t S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). This peptide also inhibits Escher
Evidence 11 Activity

Activity

MIC
Antiparasitic
10-20 µM

Target

Escherichia coli D31

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against Gram-negative bacteria E. coli D31 (MIC 10-20 uM) and weakly active against yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this
Evidence 12 Activity

Activity

MIC
Antiparasitic
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menouse
Evidence 13 Activity

Activity

MIC
Antiparasitic
25 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

cans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J
Evidence 14 Activity

Activity

MIC
Antiparasitic
6.25 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

(this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402).
Evidence 15 Activity

Activity

MIC
Antiparasitic
6.25 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

t S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). This peptide also inhibits Escher
Evidence 16 Activity

Activity

MIC
Antiviral
10-20 µM

Target

Escherichia coli D31

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against Gram-negative bacteria E. coli D31 (MIC 10-20 uM) and weakly active against yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this
Evidence 17 Activity

Activity

MIC
Antiviral
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

yeast C. glabrata ATCC 2001 C. albicans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menouse
Evidence 18 Activity

Activity

MIC
Antiviral
25 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

cans clinical isolate (this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J
Evidence 19 Activity

Activity

MIC
Antiviral
6.25 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

(this ref). Also active against S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402).
Evidence 20 Activity

Activity

MIC
Antiviral
6.25 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

t S. aureus USA300 MRSA (MIC 3.1 uM), E. coli (MIC 25 uM), B. subtilis (MIC 6.25 uM), and P. aeruginosa (MIC 6.25 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). This peptide also inhibits Escher
Evidence 21 Activity

Activity

Neurotoxin
FUNCTION: Forms pore that permeabilize the cell membrane. Promotes efflux of calcium from synaptosomes, causes hemolysis, and dissipates voltage gradients across muscle membrane. Potently inhibits the growth of bacteria, yeast and Leishmania. Is lethal to lepidopteran larvae. May function both in the prey capture strategy as well as protection from infectious organisms arising from prey ingestion. {ECO:0000269|PubMed:18098329, ECO:0000269|PubMed:9442044}.

Source & Reference

NA
UniProtKB/Swiss-Prot Tox-Prot

Other

Hogna carolinensis (Carolina wolf spider) (Lycosa carolinensis)
Neurotoxin
Forms pore that permeabilize the cell membrane. Promotes efflux of calcium from synaptosomes, causes hemolysis, and dissipates voltage gradients across muscle membrane.
M-lycotoxin-Hc1a (M-LCTX-Hc1a) (Lycotoxin I) (Lycotoxin-1)
spider
Cationic peptide 04 (cupiennin) family, 05 subfamily
Evidence at protein level
Amidation Antibiotic Antimicrobial Cytolysis Direct protein sequencing Hemolysis Ion transport Membrane Neurotoxin Secreted Target cell membrane Target membrane Toxin Transmembrane Transport
TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305|PubMed:9442044}.
Evidence 22 Activity

Activity

55% Hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
55% Hemolysis | 200 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Lycotoxins, antimicrobial peptides from venom of the wolf spider Lycosa carolinensis. | J Biol Chem | 1998
Evidence 23 Activity

Activity

50% Hemolysis
Toxicity
125 µM
Hemolytic Cytotoxic
50% Hemolysis | 125 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300. | Int J Antimicrob Agents | 2012
Evidence 24 Activity

Activity

50% Cell death
Toxicity
2.4 µM
Cytotoxic
50% Cell death | 2.4 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 25 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.
Additional Detail Fields 7 fields
Amidation Antibiotic Antimicrobial Cytolysis Direct protein sequencing Hemolysis Ion transport Membrane Neurotoxin Secreted Target cell membrane Target membrane Toxin Transmembrane Transport
Neurotoxin
Evidence at protein level
Cationic peptide 04 (cupiennin) family, 05 subfamily
M-lycotoxin-Hc1a (M-LCTX-Hc1a) (Lycotoxin I) (Lycotoxin-1)
TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305|PubMed:9442044}.
spider